کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3027469 | 1182973 | 2012 | 4 صفحه PDF | دانلود رایگان |

We determined in a prospective cohort of patients treated with vitamin K antagonists for venous thrombosis, the course of factor VIII (FVIII:C), C-reactive protein (CRP) and fibrinogen levels, to assess the influence of the acute phase reaction on FVIII:C levels. Second, we hypothesized that patients with preceding infectious symptoms might have higher levels of FVIII:C at baseline than patients without those.We included 75 patients. Blood was sampled at baseline, once during treatment (t = 1) and at the end of treatment (t = 2). Mean levels of FVIII:C were 207, 186 and 175 IU/dL (p for trend 0.003) at baseline, t = 1 and t = 2 respectively. Eight-eight percent of patients had an elevated FVIII:C at baseline, 75% at t = 1 and 72% at t = 2 (p for trend 0.045). Mean levels of FVIII:C were not different in patients with or without preceding infectious symptoms (206 versus 205 IU/dL respectively). A baseline CRP level below 62 mg/L could best distinguish between patients who will keep an elevated FVIII:C and those who will drop below 150 IU/dL.We conclude that FVIII:C levels are partially influenced by the acute phase reaction, especially in patients who keep a persistent elevated FVIII:C during treatment.Preceding infectious symptoms did not influence baseline FVIII:C levels.
Journal: Thrombosis Research - Volume 129, Issue 2, February 2012, Pages 183–186